Molecular and Cellular Immunology Core

分子和细胞免疫学核心项目摘要 作为流式细胞术，细胞分选和无数免疫服务的单一研究资源， 夏威夷大学（UH）和整个夏威夷州的分子和细胞免疫学（MCI）核心 对提高研究生产力，增强研究竞争力， 提高COBRE第一和第二阶段的赠款成功率。外部资助的研究严重依赖于 在MCI核心上，预计在第三阶段COBRE期间和之后，需求将增长。 COBRE第三阶段的目标是促进MCI核心向可持续的最先进技术的过渡 核心设施，能够支持新的，新兴的和重新出现的传染病的高水平研究 疾病，以及其他科学研究领域，将通过（1）加强和精简核心 （2）扩大用户基础、能力、容量和覆盖面并使之多样化;（3）加强 核心基础设施。就目标1而言，将进行需求评估和用户满意度调查， 确保核心业务的效率和有效性。此外，指导和培训当前和未来的 用户将更好地整合，并与传染病研究培训计划建立伙伴关系。 疾病和免疫学。就目标2而言，外联和营销活动将扩大到其他地方， 学术机构，生物技术公司和UH系统以外的医院，以及强大的合作伙伴关系将 与位于其他COBRE、INBRE和IDEA-CTR计划中的类似核心一起形成， 核心用户群，并获得新的工具和技术。此外，MCI核心将利用现有的 亚太区域研究培训实验室的基础设施，以促进国际合作 research.至于目标3，将在第三阶段制定可持续性和分阶段实施的业务计划 在COBRE期间，利用多种渠道的内部和外部支持来维持核心。定期 评估和审查核心的财政健康状况将允许对影响核心的关键因素进行必要的重组， 偿付能力，以指导在COBRE第三阶段支持之后维持核心的努力。 MCI核心预计将实现上述各项具体目标。5万美元的坚定承诺 在第三阶段COBRE期间之后的五年内，由JABSOM院长每年提供一个重要的 在这种竞争激烈和不确定的融资环境下， 继续开展核心业务，前景是增加赠款的成功率和核心业务的可持续性。

Project Summary for the Molecular and Cellular Immunology Core As the singular research resource for flow cytometry, cell sorting and myriad immunological services at the University of Hawaii (UH) and in the entire State of Hawaii, the Molecular and Cellular Immunology (MCI) Core has had a significant impact on increasing research productivity, enhancing research competitiveness and heightening grants success during COBRE Phases I and II. Extramurally funded research is heavily dependent on the MCI Core, and the need is anticipated to grow during and beyond the Phase III COBRE period. The Phase III COBRE objective of facilitating the transition of the MCI Core into a sustainable state-of-the-art core facility capable of supporting high-caliber research on new, emerging and re-emerging infectious diseases, as well as other fields of scientific inquiry, will be achieved by (1) enhancing and streamlining core operations; (2) growing and diversifying the user base, capability, capacity and reach; and (3) strengthening the core infrastructure. For Aim 1, needs assessments and user satisfaction surveys will be conducted to ensure efficiency and effectiveness of core operations. Also, mentoring and training of current and prospective users will be better integrated, and partnerships will be formed with research training programs in infectious diseases and immunology. For Aim 2, outreach and marketing activities will be expanded to other local academic institutions, biotech companies and hospitals beyond the UH System, and strong partnerships will be formed with similar cores located in other COBRE, INBRE and IDeA-CTR programs to grow and diversify the core user base and to acquire new tools and techniques. Also, the MCI Core will leverage the existing infrastructure of research training laboratories in the Asia-Pacific region to facilitate international collaborative research. And for Aim 3, sustainability and phased-in business plans will be developed during the Phase III COBRE period to draw on multiple avenues of intramural and extramural support to sustain the Core. Periodic evaluation and review of the Core's fiscal health will allow necessary restructuring of the key elements affecting solvency to guide efforts to sustain the Core beyond Phase III COBRE support. The MCI Core is expected to achieve each of the above-stated specific aims. A strong commitment of $50,000 per year for five years beyond the Phase III COBRE period, by the JABSOM Dean, will provide an important hedge against uncertain revenue streams during this competitive and uncertain funding climate and will ensure continued core operations, with the prospect of increased grants success and core sustainability.